Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGX818 (encorafenib) monotherapy and combinations in BRAF V600 melanoma
NCT01820364Phase 2Terminated
- Sponsor
- Array BioPharma
- Start
- Nov 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of encorafenib in melanoma, sponsored by Array BioPharma. Started Nov 2013; status: terminated.
02
Drugs
encorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01820364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01820364.